News | February 06, 2025
JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The scheme is fully digitized and covers approximately 45% of India's population
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Exploring new opportunities within the fast-growing market of microfluidics
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
Subscribe To Our Newsletter & Stay Updated
